Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori-positive functional dyspepsia after successful eradication therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 11, 2005, Pages 1652-1660

  Suzuki, Hidekazu ^a,b   Masaoka, Tatsuhiro ^a   Sakai, Gen ^a   Ishii, Hiromasa ^a   Hibi, Toshifumi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

Author keywords

Eradication; Questionnaire survey; Subtype of functional dyspepsia; Symptom

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; PROKINETIC AGENT; STOMACH SECRETION INHIBITOR; 2 [[(2 PYRIDYL)METHYL]SULFINYL]BENZIMIDAZOLE DERIVATIVE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; DRUG DERIVATIVE; OMEPRAZOLE;

ABDOMINAL DISEASE; ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIUM CULTURE; CHRONIC DISEASE; CONTROLLED STUDY; DYSPEPSIA; ERADICATION THERAPY; FEMALE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL SYMPTOM RATING SCALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; TREATMENT OUTCOME; UREA BREATH TEST; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; MICROBIOLOGY; MIDDLE AGED; PAIN ASSESSMENT; PATHOPHYSIOLOGY; STOMACH ULCER;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ABDOMINAL PAIN; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DYSPEPSIA; FEMALE; GASTROINTESTINAL DISEASES; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL TRACT; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PAIN MEASUREMENT; QUALITY OF LIFE; QUESTIONNAIRES; STOMACH ULCER;

EID: 12744262569     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.04039.x     Document Type: Article

References (25)

1. Talley NJ, Phillips SF, Melton J 3rd, Wiltgen C, Zinsmeister AR. A patient questionnaire to identify bowel disease. Ann. Intern. Med. 1989 111 : 671 4.
2. Thompson WG, Heaton KW. Functional bowel disorders in apparently healthy people. Gastroenterology 1980 79 : 283 8.
3. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 (Suppl. II 37 42.
4. Mearin F, Cucala M, Aspiroz F, Malagelada JF. The origin of symptoms of the brain-gut axis in functional dyspepsia. Gastroenterology 1991 101 : 999 1006.
5. The Japanese Society for Helicobacter Research. 2003 revision of the guidelines on the diagnosis and treatment of H. pylori infection. Jpn. J. Helicobacter Res. 2003 4 : 2 17.
6. Svedlund J, Sjodin I, Dotevall G. GSRS - a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988 33 : 129 34.
7. Tucci A, Corinaldesi R, Stanghellini V et al. Helicobacter pylori infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 1992 103 : 768 74.
8. Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group. BMJ 1999; 318 : 833 7.
9. McColl K, Murray L, El-Omar E et al. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N. Engl. J. Med. 1998 339 : 1869 74.
10. Stewart AL, Greenfield S, Hays RD et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcomes Study. JAMA 1989 262 : 907 13.
11. Reilly TG, Ayres RC, Poxon V, Walt RP. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol. Ther. 1995 9 : 483 90.
12. Wilhelmsen I. Quality of life and Helicobacter pylori eradication. Scand. J. Gastroenterol. Suppl. 1996 221 : 18 20.
13. Verma S, Giaffer MH. Helicobacter pylori eradication ameliorates symptoms and improves quality of life in patients on long-term acid suppression. A large prospective study in primary care. Dig. Dis. Sci. 2002 47 : 1567 74.
14. Laine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann. Intern. Med. 2001 134 : 361 9.
15. Talley NJ, Vakil N, Ballard ED 2nd, Fennerty MB. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. N. Engl. J. Med. 1999 341 : 1106 11.
16. Miwa H, Hirai S, Nagahara A et al. Cure of Helicobacter pylori infection does not improve symptoms in non-ulcer dyspepsia patients - a double-blind placebo-controlled study. Aliment Pharmacol. Ther. 2000 14 : 317 24.
17. Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst. Rev. 2003; CD002096.
18. Azuma T, Ito Y, Suto H et al. The effect of Helicobacter pylori eradication therapy on dyspepsia symptoms in industrial workers in Japan. Aliment Pharmacol. Ther. 2001 15 : 805 11.
19. Kamada T, Haruma K, Hata J et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol. Ther. 2003 18 : 245 52.
20. Haruma K, Mihara M, Okamoto E et al. Eradication of Helicobacter pylori increases gastric acidity in patients with atrophic gastritis of the corpus-evaluation of 24-h pH monitoring. Aliment Pharmacol. Ther. 1999 13 : 155 62.
21. Suzuki H, Mori M, Sakaguchi AA et al. Enhanced levels of C-X-C chemokine, human GROa, in H. Pylori-associated gastric disease. J. Gastroenterol. Hepatol. 1998; 13 : 516 520.
22. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999 402 : 656 60.
23. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat. Rev. Neurosci. 2001 2 : 551 60.
24. Suzuki H, Masaoka T, Hosoda H et al. Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio - a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology 2004; 51 : 1249 54.
25. Suzuki H, Masaoka T, Hosoda H et al. Helicobacter pylori infection modifies gastric and plasma ghrelin dynamics in Mongolian gerbils. Gut 2004 53 : 187 94.